SETD7 and prostate carcinoma: K162 methylation of PD-L1 regulates PD-1/PD-L1 interaction, significantly enhances the inhibition of T cell activity controlling cancer immune surveillance 32, and another study reported that SETD7 primarily acts as a transcriptional inhibitor in prostate cancer by methylating the K270 site of FOXA1, which disrupts FOXA1-mediated transcription 33.